stqs0428的个人博客分享 http://blog.sciencenet.cn/u/stqs0428

博文

Denosumab 是种人单克隆抗体,可结合并抑制RANKL的受体激活剂 | MedChemExpress (MCE)

已有 258 次阅读 2024-6-24 09:38 |系统分类:科研笔记

Denosumab

国际站:Denosumab

CAS:615258-40-7

品牌:MedChemExpress (MCE)

存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性: Denosumab 是一种人单克隆抗体,可结合并抑制 RANKL (TNFSF11) 的受体激活剂。 Denosumab 可以降低脊椎、非脊椎和髋部骨折的风险[1],还具有抗癌活性[2]

参考文献:[1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.[2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.



https://wap.sciencenet.cn/blog-3506747-1439478.html

上一篇:1,2-Distearoyl-sn-glycero-3-phosphorylcholine | MCE
下一篇:N,N,N\',N\'-Tetracyclohexyl-3-oxapentanediamide | MCE
收藏 IP: 222.71.56.*| 热度|

0

该博文允许注册用户评论 请点击登录 评论 (0 个评论)

数据加载中...

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2024-6-28 23:56

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部